Denial rates are approaching 20% at many provider organizations — and more than 60% of those denials go unappealed, according to Oliver Wyman’s 2026 Healthcare RCM Survey of more than 200 decision-makers. For orthopedic practices, a 10% denial rate on a surgical revenue mix alone translates to $25,000 to $100,000 in delayed or lost collections annually — and that figure compounds when denials are never challenged. At the 2026 AGS Health Summit and HIMSS 2026, revenue cycle leaders were direct: the practices protecting margin are the ones building systematic denial prevention and recovery workflows, not just tracking denials after the fact. The revenue lost to unappealed denials is not gone. It is sitting in a queue.
1. Revenue Cycle Impact: Denial Rates Are Not Stabilizing
The Oliver Wyman 2026 Healthcare RCM Survey — drawing on data from more than 200 provider organizations including medical groups, health systems, and outpatient facilities — documents denial rates approaching 20% across multiple environments. That is nearly 1 in 5 claims coming back rejected, a rate that reflects years of escalating payer complexity, AI-driven payer review tools, and documentation requirements that most specialty practices have not restructured their workflows to meet. For orthopedics, anesthesia, and pain management practices where high-dollar surgical cases are the core of the revenue mix, a sustained denial rate at this level is a structural financial risk — not a billing department problem. Separate research confirms that 41% of providers now report denial rates of 10% or higher, with initial denials continuing to trend upward year over year.
2. Revenue Cycle Impact: The 60% Unappealed Problem Is Where Revenue Disappears
The more damaging finding in the Oliver Wyman data is not the denial rate itself — it is that more than 60% of denied claims are never appealed. Across the healthcare industry, this represents hundreds of millions of dollars in recoverable revenue being permanently written off. For specialty practices, the calculus is straightforward: a 10% denial rate on surgical volume costs orthopedic practices $25,000 to $100,000 annually in delayed or lost collections depending on volume. A multi-provider orthopedic or pain management group with no systematic appeals process is compounding those losses across every physician on staff. The revenue from those denied claims has been earned. The care has been delivered. The failure is operational, not clinical — and it is fixable with the right recovery workflow.
3. Revenue Cycle Impact: The Shift to Prevention Before the Claim Leaves the Office
At HIMSS 2026, the clearest consensus among revenue cycle leaders was that denial management must move upstream. Catching a denial after submission means fighting a payer’s decision timeline, documentation requirements, and appeals process — an expensive, labor-intensive loop. The practices outperforming on denial metrics are using clinical documentation improvement, coding accuracy checks, and pre-bill claim scrubbing to surface documentation gaps, missing medical-necessity support, and coding mismatches before a claim is submitted. When AI is deployed as part of this pre-bill process — not as a standalone tool but integrated with human expert review — it identifies high-risk claims before they enter the payer’s system. This shift-left approach is what STAT News described in March 2026 as “turning the revenue cycle into an operating system” — one where denials are predicted and prevented, not just catalogued.
4. Revenue Cycle Impact: 92% of Healthcare Executives Agree — Denial Recovery Is a No-Regret Investment
Oliver Wyman’s survey found that 92% of healthcare executive respondents agreed there are no-regret investments to make in revenue cycle management right now. Denial prevention and recovery ranked at the top alongside coding automation and electronic prior authorization. Separately, 72% of executives identified technology and automation as their highest-priority RCM investment for the next 12 months — a signal that the industry has moved past debating whether to invest in denial management infrastructure and into execution. At the 2026 AGS Health Summit, RCM leaders highlighted that combining automation with human expertise is what drives measurable results in denial recovery — reinforcing the same principle: the tool matters less than the workflow built around it.
What This Means for Specialty Practices
For orthopedic, pain management, anesthesia, and ASC-based practices, the denial data from Oliver Wyman and HIMSS 2026 is not a macro healthcare story — it is a direct financial threat. A 10% to 20% denial rate on high-dollar surgical revenue, compounded by a 60% unappealed rate, means the average specialty practice is permanently losing revenue it earned and delivered. A 10% denial rate translates to $25,000 to $100,000 in annual losses for an orthopedic practice — before accounting for the administrative cost of tracking and reworking those claims. Practices that do not have a systematic pre-bill scrubbing process, a payer-specific appeals workflow, and measurable denial rate benchmarking are operating with a revenue leak they may not be able to see. The good news: the Oliver Wyman data confirms this revenue is recoverable — for practices that build the right process around it.
How Cosentus Helps Specialty Practices Protect Revenue
With 25 years of specialty-specific revenue cycle expertise and an R+A approach — real human experts working with artificial intelligence — Cosentus helps orthopedic, pain management, anesthesia, and ASC-based practices close the denial gap before it becomes a permanent loss. Cosentus clients have achieved revenue and collections growth of up to 30% through a proactive RCM strategy built around denial prevention, not just denial tracking.
- Scrubbing claims before submission to identify documentation gaps, coding mismatches, and medical-necessity risk before a payer ever sees the claim.
- Tracking denial rates by payer, procedure, and provider so your team knows exactly where the revenue is leaking — not just that it is.
- Managing the full appeals workflow within payer-specific timelines so no denied claim is abandoned without a recovery attempt.
- Benchmarking your denial rate against the 10% threshold and building a measurable improvement plan based on your actual claim mix.
- Combining AI-assisted denial prediction with human expert review — the same approach HIMSS 2026 identified as the standard for high-performing RCM organizations.
- Delivering the visibility your CFO needs: denial rate by payer, appeal win rate, and recovered revenue tracked in real time.
